natgillin/translations-raw huggingface dataset:
Elevated cholesterol levels 2,3 Elevated glucose levels 4 Elevated triglyceride levels 2,5 Glucosuria Increased appetite
vključ z nekaj no
35
35 Bolezni ž evja ivč zaspanost
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
36 č 1 Klinič pomembno poveč telesne mase so opazili pri vseh izhodišnih indeksih telesne mase
36
anje
37 Children and adolescents Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
Posebnih klinič
38 Management of overdose There is no specific antidote for olanzapine.
ivetju po akutnem prevelikem odmerjanju z odmerkom 1500 mg.
39 of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
V 12- meseč raziskavi o ponovitvi bolezni pri bolnikih z manič epizodo, ki so z zdravljenjem z
40 In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
V primerjavi med kadilci in nekadilci (moš in ž kimi nekadilcih podaljš (38, 6 v primerjavi s 30, 4 ure),
41 Mutagenicity Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Pri psih s citopenijo ni bilo než elenih uč inkov na progenitorne in proliferirajoč celice v kostnem mozgu. e
8.
42 Š 8.
Each tablet contains 10 mg olanzapine.
1 tableta vsebuje 10 mg olanzapina.
Each tablet contains 161.8 mg lactose.
Pomož snov: na 1 tableta vsebuje 161, 8 mg laktoze.
Tablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots and an inscription “ 10”.
Tablete so okrogle, rahlo izboč svetlo rumene barve z morebitnimi posameznimi rumenimi pikami ene, in napisom 10.
During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5- 20 mg/ day.
44 Med zdravljenjem shizofrenije in manič epizode in med prepreč
44 Olanzapine can be given without regards for meals as absorption is not affected by food.
Bolniki lahko jemljejo olanzapin ne glede na obroke, ker hrana ne vpliva na absorpcijo.
When more than one factor is present which might result in slower metabolism (femal e gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose.
Č je prisoten več en dejavnik, ki bi lahko prispeval k poč
45 with olanzapine compared to patients treated with placebo (1.3% vs.
45 smrtnost, neodvisno od omenjenih dejavnikov tveganja, več pri bolnikih, zdravljenih z olanzapinom, ja kot pri bolnikih, zdravljenih s placebom.
46 Neutropenia Caution should be exercised in patients with low leukocyte and/ or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/ toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
Previdnost je prav tako potrebna pri bolnikih, ki so imeli v preteklosti tež zaradi ave zavrtega delovanja kostnega mozga, ki so ga povzroč zdravila, toksič za kostni mozeg, pri
47 Lactose Zalasta tablets contain lactose.
47 Olanzapin ni indiciran za zdravljenje otrok in mladostnikov.
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
48 Interval QTc Č predpisujemo olanzapin soč e asno z zdravili, za katera je znano, da podaljš ujejo interval QTc, je potreba previdnost (gl. poglavje 4. 4).
48 4.6 Pregnancy and lactation
4. 6 Noseč in dojenje nost
49
49 Bolezni ž evja ivč zaspanost
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
50 č 1 Klinič pomembno poveč telesne mase so opazili pri vseh izhodišnih indeksih telesne mase
50
anje
51 Children and adolescents Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
Posebnih klinič
52 Management of overdose There is no specific antidote for olanzapine.
ivetju po akutnem prevelikem odmerjanju z odmerkom 1500 mg.
In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition
V raziskavi, v kateri so vsaj dva tedna spremljali sočasno zdravljenje bolnikov z litijem ali valproatom, je dodatek 10 mg olanzapina bolj zmanjš jakost simptomov manije po 6 tednih kot pri monoterapiji z litijem ali al valproatom.
53 of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
V 12- meseč raziskavi o ponovitvi bolezni pri bolnikih z manič epizodo, ki so z zdravljenjem z
54 In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
V primerjavi med kadilci in nekadilci (moš in ž kimi nekadilcih podaljš (38, 6 v primerjavi s 30, 4 ure),
55 Mutagenicity Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Pri psih s citopenijo ni bilo než elenih uč inkov na progenitorne in proliferirajoč celice v kostnem mozgu. e
7, 14, 28, 35, 56 or 70 tablets in a box.
7, 14, 28, 35, 56 ali 70 tablet, v š katli.
8.
56 Š 8.
Each tablet contains 15 mg olanzapine.
1 tableta vsebuje 15 mg olanzapina.
Each tablet contains 242.7 mg lactose.
Pomož snov: na 1 tableta vsebuje 242, 7 mg laktoze.
Tablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots and an inscription “ 15”.
Tablete so okrogle, rahlo izboč svetlo rumene barve z morebitnimi posameznimi rumenimi pikami ene, in napisom 15.
58 Olanzapine can be given without regards for meals as absorption is not affected by food.
58 Med zdravljenjem shizofrenije in manič epizode in med prepreč
59 with olanzapine compared to patients treated with placebo (1.3% vs.
59 smrtnost, neodvisno od omenjenih dejavnikov tveganja, več pri bolnikih, zdravljenih z olanzapinom, ja kot pri bolnikih, zdravljenih s placebom.
60 Neutropenia Caution should be exercised in patients with low leukocyte and/ or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/ toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
Previdnost je prav tako potrebna pri bolnikih, ki so imeli v preteklosti tež zaradi ave zavrtega delovanja kostnega mozga, ki so ga povzroč zdravila, toksič za kostni mozeg, pri
61 Lactose Zalasta tablets contain lactose.
61 Olanzapin ni indiciran za zdravljenje otrok in mladostnikov.
CNS medicinal products Caution should be exercised in patients who receive medicinal products that can cause central nervous system depression and alcohol.
Pri bolnikih, ki pijejo alkohol ali jemljejo zdravila, ki lahko povzroč depresijo osrednjega ž evja, je potrebna previdnost.
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
62 Interval QTc Č predpisujemo olanzapin soč e asno z zdravili, za katera je znano, da podaljš ujejo interval QTc, je potreba previdnost (gl. poglavje 4. 4).
62 4.6 Pregnancy and lactation
4. 6 Noseč in dojenje nost
63
63 Bolezni ž evja ivč zaspanost
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
64 č 1 Klinič pomembno poveč telesne mase so opazili pri vseh izhodišnih indeksih telesne mase
64
anje
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
holesterolov LDL in HDL ali trigliceridov se je sč asoma poveč Pri odraslih bolnikih, ki so konč 9 - do 12- meseč zdravljenje, se je poveč
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’ s disease, worsening of Parkinsonian symptomatology and ha llucinations were reported very commonly and more frequently than with placebo.
ali
Speech disorder was also reported commonly.
približ 4 do 6 no
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
no mesecih.
Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.
evanje povpreč vrednosti glukoze v krvi upoč nih
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Dodatne informacije glede posebnih skupin bolnikov V klinič preizkuš
Very common (≥ 10%), common (≥ 1% and < 10%).
anjih na starejš bolnikih z demenco je bilo zdravljenje z olanzapinom v ih
Weight gain9, elevated triglyceride levels10, increased appetite.
primerjavi s placebom povezano z več smrtnostjo in pogostejš mož
11 Common:
imi
Gastrointestinal disorders Common:
ganskož ilnimi neželenimi
Elevations of hepatic transaminases (ALT/ AST; see section 4.4).
dogodki (gl. poglavje 4. 4).
Among adolescent patients, mean weight gain was greatest in patients who were overweight or obese at baseline.
Zelo pogosta než elena uč inka, povezana z jemanjem olanzapina, v tej skupini bolnikov sta bila neobič hoja in padci.
12 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
Pogosto so opaž pljuč
4.9 Overdose
ajna
Signs and symptoms Very common symptoms in overdose (> 10% incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
nico, poviš
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2% of overdose cases) and cardiopulmonary arrest.
telesno ano
66 Management of overdose There is no specific antidote for olanzapine.
temperaturo, letargijo, eritem, vidne halucinacije ter inkontinenco urina.
Induction of emesis is not recommended.
V klinič preizkuš
Standard procedures for management of overdose may be indicated (i. e. gastric lavage, administration of activated charcoal).
nih
The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.
anjih na bolnikih s psihozami, ki so jih povzroč zdravila (dopaminski agonisti), ila
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta- agonist activity since beta stimulation may worsen hypotension.
povezana s Parkinsonovo boleznijo, so pogosto ter pogosteje kot pri placebu poroč o poslabš simptomatike Parkinsonove bolezni in halucinacijah.
Cardiovascular monitoring is necessary to detect possible arrhythmias.
V enem klinič preizkuš na bolnikih z bipolarno motnjo je kombinirano zdravljenje z
5.
nem
PHARMACOLOGICAL PROPERTIES
anju
5.1 Pharmacodynamic properties
valproatom in olanzapinom povzroč nevtropenije pri 4, 1% bolnikov; mož vzroč dejavnik so
N05AH03.
ilo
Olanzapine is an antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.
ni
Animal behavioral studies with 1 olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor- binding profile.
lahko poveč plazemske koncentracije valproata.
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo, models.
Pogosto
Electrophysiological studies demonstrated that olanzapine selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on the striatal (A9) pathways involved in motor function.
il
In a single oral dose (10 mg) Positron Emission tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy.
nejš
In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.
an
In a multinationational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p=0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).
anje
In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
so poroč tudi o motnji govora.
In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali ali divalproeksom se je 17, 4% bolnikov med akutnim zdravljenjem (do 6 tednov) poveč telesna masa, ala
67 of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
Dolgotrajno zdravljenje z olanzapinom (do 12 mesecev) za prepreč evanje ponovnega pojava bolezni pri bolnikih z bipolarno motnjo je bilo povezano s anjem telesne mase za ≥% z osnovne pri 39, 9% bolnikov. poveč 7
Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recur rence into mania or recurrence into depression.
Posebnih klinič
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p = 0.055).
ih
In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.
nih
During treatment with olanzapine, adolescents gained significantly more weight compared with adults.
raziskav, v katerih bi primerjali mladostnike in odrasle, niso izvedli, so pa podatke iz preizkuš na anj mladostnikih primerjali s podatki iz preizkuš na odraslih. anj
5.2 Pharmacokinetic properties
Naslednja tabela vključ než
Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours.
uje
The predominant pharmacologic activity is from the parent olanzapine.
elene učinke, ki so bili pogostejšpri mladostnikih (starih od 13 do i
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/ hr).
17 let) kot pri odraslih bolnikih, in než elene uč inke, ki so jih ugotovili samo v kratkotrajnih klinič nih preizkuš anjih na mladostnikih.
The pharmacokinetic variability observed in the elderly is within the range for the non-elderly.
Iz podatkov je razvidno, da je klinič pomembno poveč telesne
In 44 patients with schizophrenia 65 years of age, dosing from 5 to 20 mg/ day was not associated with any distinguishing profile of adverse events.
anje
In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hr) and the clearance was reduced (18.9 versus 27.3 l/ hr).
mase (≥7%) pogostejš pri mladostnikih kot pri odraslih.
However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n=467) as in male patients (n=869).
Obseg poveč telesne mase in delež
In renally impaired patients (creatinine clearance < 10 ml/ min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/ hr).
e
68 In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
anja
In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/ hr).
mladostnikov, pri katerih se je telesna masa klinič znač poveč sta bila pri dolgotrajni
The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers.
no
In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.
ilno
1
ala,
Paediatric population Adolescents (ages 13 to 17 years):
izpostavljenosti (najmanj 24 tednov) več kot pri kratkotrajni. ja
In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents.
Neželeni uč so navedeni po padajočresnosti, njihova pogostost pa je definirana z opisoma zelo
5.3 Preclinical safety data
inki
Acute (single-dose) toxicity Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain.
i
Repeated-dose toxicity In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders.
pogosti (≥10%) in pogosti (≥1% in < 10%).
Tolerance developed to the CNS depression.
Pogostost než elenih uč inkov
Reversible effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and morphologic changes in vaginal epithelium and in mammary gland.
Presnovne in prehranske motnje zelo pogosti: poveč telesne mase9, zviš ravni trigliceridov10, poveč apetit pogosti: zviš ravni ane Bolezni ž evja ivč
Haematologic toxicity:
anje holesterola 11
Reproductive toxicity Olanzapine had no teratogenic effects.
ane
69 Mutagenicity Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
an
Carcinogenicity Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
zelo pogosti: sedacija (vključ s hipersomnijo, letargijo, zaspanostjo) no Bolezni prebavil pogosti: suha usta Bolezni jeter, ž nika in ž evodov
6.
olč
6.1 List of excipients
olč
Lactose monohydrate Powdered cellulose Pregelatinised maize starch Maize starch Colloidal anhydrous silica Magnesium stearate
zelo pogosti: zviš ravni jetrnih transaminaz (ALT/ AST; gl. poglavje 4. 4) ane Preiskave zelo pogosti: nizke ravni skupnega bilirubina, visoka raven GGT (gama- glutamil transferaze), poveč plazemske koncentracije prolaktina12 ane
6.2 Incompatibilities
Med mladostniki je bilo č povpreč poveč več pri bolnikih, ki so bili v osnovi predebeli ali debeli.
Not applicable.
no
6.3 Shelf life
anje
2 years.
je
6.4 Special precautions for storage
10
This medicinal product does not require any special storage conditions.
č
6.5 Nature and contents of container
Opazovano pri normalnih osnovnih vrednostih na teše (< 1, 016 mmol/ l), ki so se zviš na visoke ale č (≥1, 467 mmol/ l).
14, 28, 35, 56 or 70 tablets in a box.
Vrednosti trigliceridov na teše so se z mejnih osnovnih vrednosti (≥1, 016 mmol/ l do < 1, 467 mmol/ l) spremenile na visoke (≥1, 467 mmol/ l).
Not all pack sizes may be marketed.
č 11 Pogosto so opazovali spremembe vrednosti skupnega holesterola na teše, ki so se z normalnih osnovnih vrednosti (< 4, 39 mmol/ l) zviš na visoke (≥
6.6 Special precautions for disposal
ale
Any unused product or waste material should be disposed of in accordance with local requirements.
č
MARKETING AUTHORISATION HOLDER
Zelo pogoste so bile
KRKA, d. d., Novo mesto, Š marješ cesta 6, 8501 Novo mesto, Slovenia ka
12 O poveč plazemskih koncentracijah prolaktina so poroč pri 47, 4% mladostnikov.
8.
anih
EU/ 1/ 07/ 415/ 022-026
ali
9.
4. 9 Preveliko odmerjanje
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
Znaki in simptomi Zelo pogosti simptomi pri prevelikem odmerjanju (incidenca > 10%) vključ ujejo tahikardijo, vznemirjenost/ nasilnost, dizartrijo, različ ekstrapiramidne simptome in motnje zavesti v razponu od ne sedacije do kome.
27 September 2007.
66 Druge zdravstveno pomembne posledice prevelikega odmerjanja vključ
DATE OF REVISION OF THE TEXT
ujejo delirij, konvulzije, komo,
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
mož nevroleptič maligni sindrom, depresijo dihanja, aspiracijo, hipertenzijo ali hipotenzijo,
71 1.
en
Zalasta 20 mg tablets
ni
2.
Poroč
QUALITATIVE AND QUANTITATIVE COMPOSITION
ali
Each tablet contains 20 mg olanzapine.
so o smrtnih izidih po akutnih prevelikih odmerjanjih tako majhnih odmerkov, kot je 450 mg, vendar so poroč tudi o prež
Excipient:
ali
Each tablet contains 323.5 mg lactose.
ivetju po akutnem prevelikem odmerjanju z odmerkom 1500 mg.
For a full list of excipients, see section 6.1.
Sprož bruhanja ni priporoč Lahko so indicirani
3.
enje
Tablet.
eno.
Tablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots and an inscription “ 20”.
Ne uporabljajte adrenalina, dopamina ali drugih simpatikomimetikov z betaagonistič delovanjem, ker lahko beta stimulacija poslabš
4.
nim
4.1 Therapeutic indications
a
Adults Olanzapine is indicated for the treatment of schizophrenia.
S skrbnim
Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.
zdravstvenim nadzorovanjem in opazovanjem je treba nadaljevati, dokler si bolnik ne opomore.
Olanzapine is indicated for the treatment of moderate to severe manic episode.
FARMAKOLOŠ LASTNOSTI KE
In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1).
5. 1 Farmakodinamič lastnosti ne
4.2 Posology and method of administration
N05AH03.
The recommended starting dose for olanzapine is 10 mg/ day.
enja, ki kaž š farmakološ profil prek Olanzapin je antipsihotik, antimanik in stabilizator razpoliž številnih receptorskih sistemov.
Manic episode:
nih nih
The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).
1
The recommended starting dose is 10 mg/ day.
receptorjev H1.
For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose.
Vedenjske raziskave na živalih so kazale na 5- HT, dopaminski in holinergič antagonizem v skladu s profilom vezave na receptorje.
If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.
V pogojih in vitro je olanzapin pokazal več